Pharmaxis Of Australia Readies Europe Application For Bronchitol
This article was originally published in PharmAsia News
Executive Summary
Australia's Pharmaxis says it is ready to apply for approval of its Bronchitol (mannitol) dry powder to treat cystic fibrosis in Europe. The company said it was acting on the basis of positive returns from a Phase III trial in Europe. The drug is intended to reduce mucus build-up in the lungs of patients with chronic respiratory problems. Pharmaxis also is recruiting participants for a U.S. trial. (Click here for more